ABT vs BSX vs ISRG Stock Comparison

Abbott Laboratories, Boston Scientific and Intuitive Surgical Prices as of Nov 13, 2026 Peers: Industry group
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$186.63B
P/E
39.7x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
3 wins
BSX Boston Scientific Corp
$44.34 +3.1% 1M -57.8% 1Y
Market cap
$63.47B
P/E
18.1x
Revenue (TTM)
$21.07B
Div. yield
–
Medical Devices Healthcare
4 wins
ISRG Intuitive Surgical Inc
$443.59 +5.6% 1M -21.6% 1Y
Market cap
$152.73B
P/E
51.6x
Revenue (TTM)
$11.58B
Div. yield
–
Medical Devices Healthcare
4 wins

Head to Head

11 decided of 12

Boston Scientific leads on 4 of the 12 questions below (Boston Scientific 4, Intuitive Surgical 4, Abbott Laboratories 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABTBSXISRGLeader
Larger companyMarket capitalisation $186.63B $63.47B $152.73B ABT
Cheaper on earningsLower P/E, profitable companies only 39.7x 18.1x 51.6x BSX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.1x 14.5x 38.5x BSX
Faster revenue growthRevenue growth, trailing twelve months +10.0% +8.9% +20.5% ISRG
More profitableNet margin, trailing twelve months 9.7% 16.6% 25.5% ISRG
Better return on capitalReturn on invested capital 5.7% 9.9% — BSX
Less leveragedLower net debt / EBITDA 2.5x 2.1x — BSX
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -16.0% -57.8% -21.6% ABT
Better 5-year returnAnnualised price return, 5 years -3.3%/yr +1.1%/yr +4.6%/yr ISRG
Less volatileAnnualised volatility, 1 year 28.5% 41.5% 36.1% ABT
Higher overall scoreMean of the five percentile scores vs peers 56/100 68/100 81/100 ISRG

Percentile Scorecard

ABTBSXISRG

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABTBSXISRG
Valuation 74 #65 of 243 87 #33 of 243 52 #118 of 243
Growth 26 #168 of 228 68 #73 of 228 81 #45 of 228
Profitability 82 #41 of 222 91 #20 of 222 97 #7 of 222
Financial Health 33 #167 of 248 43 #142 of 248 81 #47 of 248
Shareholder Returns 65 #56 of 158 48 #82 of 158 95 #9 of 158
Overall 56 68 81
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • BSX ranked among 252 companies in Medical Devices and Diagnostics
  • ISRG ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABTBSXISRGSPY
1 month +5.4%+3.1%+5.6% -2.0%
3 months -2.4%-14.5%+12.4% -2.8%
6 months +28.5%-15.8%+5.3% +2.0%
Year to date -13.4%-53.5%-21.7% +10.6%
1 year -16.0%-57.8%-21.6% +12.2%
3 years +11.8%-17.9%+52.1% +68.1%
3 years, per year +3.8%-6.4%+15.0% +18.9%
5 years -15.5%+5.4%+25.0% +61.4%
5 years, per year -3.3%+1.1%+4.6% +10.1%
10 years +170.4%+106.2%+542.1% +248.5%
10 years, per year +10.5%+7.5%+20.4% +13.3%

Risk

MeasureABTBSXISRGSPY
Volatility, 1Y 28.5%41.5%36.1% 13.6%
Downside volatility, 1Y 27.8%47.7%38.4% 13.9%
Beta vs S&P 500, 1Y 0.070.260.92 1.00
Return / volatility, 1Y -0.56-1.39-0.60 0.90
Max drawdown, 5Y -41.6%-61.6%-49.9% -25.4%
From 52-week high -16.9%-57.8%-25.2% -3.2%
52-week high $130.59$104.98$592.85 $779.14
52-week low $82.56$41.57$332.02 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABTBSXISRG
P/E now vs peer median 40.0xmedian 26.5x 18.3xmedian 26.5x 52.4xmedian 26.5x
P/S now vs peer median 3.9xmedian 2.7x 3.1xmedian 2.7x 13.3xmedian 2.7x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 14.1xmedian 18.4x 36.6xmedian 18.4x
P/FCF now vs peer median 27.8xmedian 25.4x 19.3xmedian 25.4x 42.7xmedian 25.4x
P/B now vs peer median 3.6xmedian 2.5x 2.5xmedian 2.5x 9.5xmedian 2.5x
PEG now vs peer median -13.92median 0.98 0.42median 0.98 2.04median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABTBSXISRG
Revenue $48.23B $21.07B $11.58B
Gross profit $27.46B $14.57B $7.78B
Operating income $6.65B $3.93B $3.28B
Net income $4.70B $3.49B $2.97B
Free cash flow $6.76B $3.33B $3.60B
R&D $3.31B $2.16B $1.49B
EPS (diluted) $2.70 $2.41 $8.41
Cash & equivalents $4.05B $609.00M $2.98B
Total debt $31.16B $11.95B –
Shares (diluted) 1.74B 1.45B 351.60M
Enterprise value $160.49B $58.91B $133.02B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABTBSXISRG
P/E 40.0x 18.3x 52.4x
P/FCF 27.8x 19.3x 42.7x
P/Operating cash flow 21.2x 15.2x 37.6x
P/S 3.9x 3.1x 13.3x
P/B 3.6x 2.5x 9.5x
P/Tangible book 5.9x 3.4x 10.3x
EV/EBITDA 20.3x 14.1x 36.6x
EV/EBIT 32.3x 19.2x 45.6x
EV/Revenue 4.5x 3.6x 12.9x
EV/FCF 31.8x 22.7x 41.6x
EV/Operating cash flow 24.3x 17.9x 36.6x
PEG (3Y EPS CAGR) -13.92 0.42 2.04

Growth

14 metrics
MetricABTBSXISRG
Revenue growth (1Y) 10.0% 8.9% 20.5%
Revenue CAGR (3Y) 6.5% 15.3% 19.1%
Gross profit growth (1Y) 12.1% 9.8% 21.9%
Gross profit CAGR (3Y) 7.8% 15.1% 19.5%
Operating income growth (1Y) -13.8% 13.5% 16.6%
Operating income CAGR (3Y) 3.5% 22.1% 24.8%
Net income growth (1Y) -66.4% 25.5% 7.5%
Net income CAGR (3Y) -3.1% 41.7% 24.4%
EPS growth (1Y) -66.1% 29.2% 10.8%
EPS CAGR (3Y) -2.9% 44.0% 25.7%
Operating cash flow growth (1Y) -2.9% -8.5% 38.1%
Operating cash flow CAGR (3Y) 10.6% 21.6% 26.4%
Free cash flow growth (1Y) -2.3% -12.9% 58.4%
Free cash flow CAGR (3Y) 14.6% 25.2% 42.0%

Profitability

14 metrics
MetricABTBSXISRG
Gross margin 56.9% 69.1% 67.2%
EBITDA margin 21.9% 25.5% 35.3%
Operating margin 13.8% 18.7% 28.4%
Pretax margin 13.6% 17.3% 31.3%
Net margin 9.7% 16.6% 25.5%
FCF margin 14.0% 15.8% 31.1%
Operating cash flow margin 18.4% 20.1% 35.3%
Return on equity 9.1% 13.7% 17.3%
Return on assets 4.3% 7.7% 14.8%
Return on invested capital 5.7% 9.9% –
Return on capital employed 7.2% 10.0% 18.7%
Asset turnover 0.4x 0.5x 0.6x
Cash conversion (OCF / net income) 1.9x 1.2x 1.4x
Stock comp / revenue 1.5% 1.5% 7.2%

Financial Health

11 metrics
MetricABTBSXISRG
Debt / assets 28.8% 26.3% –
Debt / equity 0.6x 0.5x –
Net debt / EBITDA 2.5x 2.1x –
Debt / FCF 4.6x 3.6x –
Liabilities / assets 52.3% 43.1% 16.7%
Equity / assets 47.7% 56.9% 83.3%
Interest coverage 6.7x 10.5x –
Current ratio 1.5x 1.4x 3.3x
Quick ratio 0.8x 0.6x 2.3x
Cash ratio 0.3x 0.1x 1.6x
Altman Z-score 3.36 3.03 30.40

Shareholder Returns

7 metrics
MetricABTBSXISRG
Dividend yield 2.3% – –
Net buyback yield 0.7% -0.3% 2.8%
Shareholder yield 3.0% -0.3% 2.8%
Payout ratio (earnings) 92.0% – –
Payout ratio (FCF) 64.0% – –
Dividend growth (1Y) 6.9% – –
Dividend CAGR (3Y) 7.4% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABTBSXISRG
Forward P/E 19.1xFY2026 14.5xFY2026 38.5xFY2026
EPS, next fiscal year $5.69FY2026 $3.06FY2026 $11.52FY2026
EPS growth, next FY +10.5%FY2026 0.0%FY2026 +29.0%FY2026
EPS growth, the year after +10.2% +8.2% +4.5%
Revenue, next fiscal year $52.99BFY2026 $20.48BFY2026 $11.62BFY2026
Revenue growth, next FY +19.5%FY2026 +2.1%FY2026 +15.5%FY2026
Revenue growth, the year after -2.3% -4.0% +11.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABTBSXISRG
Held by institutions 79.2% 90.5% 86.2%
Institutions holding 2,983 1,484 2,241
Change in shares held, QoQ +0.3% -0.7% +4.6%
Institutions buying 1,261 738 1,073
Institutions selling 1,379 612 879
Buyers to sellers 0.91 1.21 1.22

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABTBSXISRG
ABT 1.00 0.40 0.37
BSX 0.40 1.00 0.41
ISRG 0.37 0.41 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ABT, BSX and ISRG?

Abbott Laboratories (ABT) is the largest by market capitalisation: Abbott Laboratories (ABT) $186.63B, Boston Scientific (BSX) $63.47B, Intuitive Surgical (ISRG) $152.73B.

Which stock is cheaper, ABT, BSX and ISRG?

Boston Scientific (BSX) trades on the lowest price-to-earnings ratio (Abbott Laboratories (ABT) 39.7x, Boston Scientific (BSX) 18.1x, Intuitive Surgical (ISRG) 51.6x). On next year's consensus earnings, Boston Scientific (BSX) is cheapest (Abbott Laboratories (ABT) 19.1x, Boston Scientific (BSX) 14.5x, Intuitive Surgical (ISRG) 38.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Intuitive Surgical (ISRG) grew revenue fastest over the trailing twelve months: Abbott Laboratories (ABT) +10.0%, Boston Scientific (BSX) +8.9%, Intuitive Surgical (ISRG) +20.5%.

Which company is more profitable?

Intuitive Surgical (ISRG) has the highest net margin (Abbott Laboratories (ABT) 9.7%, Boston Scientific (BSX) 16.6%, Intuitive Surgical (ISRG) 25.5%). On return on invested capital, Boston Scientific (BSX) leads (Abbott Laboratories (ABT) 5.7%, Boston Scientific (BSX) 9.9%).

Which stock has performed better?

Over the past year Abbott Laboratories (ABT) returned the most: Abbott Laboratories (ABT) -16.0%, Boston Scientific (BSX) -57.8%, Intuitive Surgical (ISRG) -21.6%. Over five years, Intuitive Surgical (ISRG) compounded fastest (Abbott Laboratories (ABT) -3.3%/yr, Boston Scientific (BSX) +1.1%/yr, Intuitive Surgical (ISRG) +4.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Abbott Laboratories (ABT) 0.02%, Boston Scientific (BSX) 0.00%, Intuitive Surgical (ISRG) 0.00%. Boston Scientific (BSX) and Intuitive Surgical (ISRG) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Abbott Laboratories (ABT) has been the steadiest (Abbott Laboratories (ABT) 28.5%, Boston Scientific (BSX) 41.5%, Intuitive Surgical (ISRG) 36.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ABT, BSX and ISRG?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Boston Scientific (BSX) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.